Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 12/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111073 | 0.90 | PTGIR (0.49) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7107090 | 0.84 | PTGIR (0.48) | PTGIRNOTUMEPHX1SGMS2 | |
| SCHEMBL7107093 | 0.84 | PTGIR (0.48) | PTGIRNOTUMEPHX1SGMS2 | |
| SCHEMBL7658900 | 0.78 | DDB1 (0.43) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7650685 | 0.77 | PTGIR (0.49) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7657611 | 0.77 | PTGIR (0.49) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7658249 | 0.76 | PTGIR (0.48) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7653485 | 0.76 | PTGIR (0.48) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL7653394 | 0.75 | PTGIR (0.46) | PTGIRPTGDR2PTGER1PTGER3PTGDR | |
| SCHEMBL27485430 | 0.74 | L3MBTL1 (0.52) | PTGIRPTGDR2PTGER1PTGER3PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335459-B1 | PROSTAGLANDIN I2 RECEPTOR MODULATORS; TREATING TISSUE NECROSIS, PREMATURE UTERINE CONTRACTION, GASTRIC ULCERATION, SEXUAL DYSFUNCTION, MENSTRUAL PAIN AND IMPROPER WOUND HEALING, IMMUNOREGULATION, PLATELET AGGREGATION OR NEUTROPHIL FUNCTION | SYNTEX (U.S.A.) LLC | 2002-01-01 | — | — | US | disclosed |